What Alkeus Pharmaceuticals does

Alkeus Pharmaceuticals, Inc. is a privately-held, clinical-stage biopharmaceutical company headquartered at 44 Brattle Street, Cambridge, Massachusetts. Founded in 2010 by Dr. Ilyas Washington and Dr. Leonide Saad, the company is developing a single lead investigational therapy, oral gildeuretinol acetate (ALK-001), a new molecular entity designed to reduce the dimerization of vitamin A in the retina without modulating the visual cycle — a mechanism intended to prevent the accumulation of toxic vitamin A dimers that drive progression of Stargardt disease and geographic atrophy secondary to age-related macular degeneration. The company is pre-revenue and has no commercialized products.

The clinical pipeline is structured around three core programs. The pivotal global Phase 3 NORTHSTAR study is enrolling approximately 230 participants aged 8 to 45 with Stargardt disease across 55 sites in more than 11 countries, with primary endpoint of atrophic lesion growth rate. The TEASE program (four studies: TEASE-1 and TEASE-2 completed, TEASE-3 and TEASE-4 ongoing) covers Stargardt patients across advanced, moderate, and early-stage disease plus an open-label extension; TEASE-1 demonstrated a 21.6% reduction in atrophic lesion growth versus placebo (p<0.001). The SAGA study in 198 patients with geographic atrophy showed a 15.3% statistically significant reduction in GA lesion growth from 6 to 24 months (p=0.047) and preservation of 4.4 letters of low luminance visual acuity (p=0.031). Cumulative exposure exceeds 400 patients with a well-tolerated safety profile.

Alkeus's business model is a standard specialty pharmaceutical one-time license / prescription-revenue model contingent on FDA approval, with planned commercialization through traditional pharmaceutical distribution channels targeting retina specialists. The company is backed by institutional investors led by Bain Capital Life Sciences, which led a $150 million Series B financing in June 2023 alongside Sofinnova Investments, TCG Crossover, and Wellington Management. Gildeuretinol has received Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, plus Orphan Medicinal Product designation from the EMA. Leadership was substantially rebuilt in 2024-2025 with the appointment of Michel Dahan (President and CEO, formerly COO of Akebia Therapeutics), David Arkowitz (CFO), Tamara Dillon (CHRO), Eric Trachtenberg (CLO), Srinivas Duggirala (SVP, Technical Operations), and Carlos Quezada-Ruiz (CMO, formerly SVP/Ophthalmology Therapeutic Area Head at 4D Molecular Therapeutics and senior leader at Genentech/Roche ophthalmology).

Name

Alkeus Pharmaceuticals

Legal name

Alkeus Pharmaceuticals, Inc.

Website

https://alkeuspharma.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Alkeus Pharmaceuticals is a private, clinical-stage biopharmaceutical company developing oral gildeuretinol acetate (ALK-001), an investigational therapy that reduces toxic vitamin A dimerization for Stargardt disease and geographic atrophy secondary to AMD. The Cambridge, Massachusetts company is conducting a pivotal global Phase 3 program.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue biopharmaceutical company developing gildeuretinol (ALK-001) for Stargardt disease and geographic atrophy. The company plans to commercialize the therapy upon FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company developing gildeuretinol acetate (ALK-001), an oral investigational therapy designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. The product is being advanced in clinical trials for Stargardt disease (TEASE program and pivotal Phase 3 NORTHSTAR study) and geographic atrophy secondary to age-related macular degeneration (SAGA study). The company is pre-revenue and intends to commercialize the therapy upon FDA approval, distributing it through traditional pharmaceutical channels prescribed by retina specialists.

Product overview

Alkeus Pharmaceuticals is a biopharmaceutical company developing a single lead candidate, gildeuretinol acetate (ALK-001), an oral new molecular entity designed to reduce toxic vitamin A dimerization without modulating the visual cycle. The product is being advanced through multiple clinical trial programs: the pivotal Phase 3 NORTHSTAR Study for Stargardt disease, the TEASE program (four studies spanning advanced, moderate, early-stage, and extension phases) for Stargardt disease, and the SAGA study for geographic atrophy secondary to AMD. The company has no commercialized products and all offerings are investigational therapies in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Gildeuretinol Acetate (ALK-001) Oral investigational new molecular entity (capsule, once daily) designed to reduce toxic vitamin A dimerization in the retina without modulating the visual cycle. It is Alkeus's lead clinical candidate, in development for Stargardt disease and geographic atrophy secondary to age-related macular degeneration.
• NORTHSTAR Phase 3 Study (Gildeuretinol) Pivotal clinical trial program evaluating oral gildeuretinol acetate in patients with Stargardt disease; designed to support regulatory approval.
• TEASE Program (TEASE-1, TEASE-2, TEASE-3, TEASE-4) Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) program—four studies across advanced, moderate, early-stage, and extension phases evaluating oral gildeuretinol in Stargardt disease.
• SAGA Study (Gildeuretinol in Geographic Atrophy) Clinical study evaluating oral gildeuretinol in 198 patients with geographic atrophy (GA) secondary to age-related macular degeneration, with the primary efficacy endpoint of GA lesion growth rate measured by Fundus Autofluorescence.

Quantifiable outcome

• 21.6% reduction in atrophic retinal lesion growth vs placebo (p<0.001) in TEASE-1 study
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Prevent BlindnesssupportingGTM or Marketing PartnerAlkeus serves as Silver Sponsor for Prevent Blindness's third annual Inherited Retinal Disease (IRD) and Genetic Testing Month initiative. The partnership supports education about Stargardt disease and genetic testing for early diagnosis and treatment planning.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Apellis Pharmaceuticals: Commercial-stage biotech with Syfovre (pegcetacoplan) approved for geographic atrophy secondary to AMD. Directly comparable to Alkeus because both target the same large GA population with a retinal-disease focus, although Apellis uses a complement-inhibitor intravitreal approach versus gildeuretinol's oral vitamin A dimerization mechanism.
• Astellas Pharma (Iveric Bio): Acquired Iveric Bio and now markets Izervay (avacincaptad pegol) for geographic atrophy secondary to AMD. A direct competitor in the GA market and a benchmark for late-stage ophthalmology biotech acquisition by big pharma — a relevant strategic exit template for Alkeus.
• 4D Molecular Therapeutics: Clinical-stage gene therapy company targeting inherited retinal diseases including ABCA4-related conditions. Highly comparable to Alkeus because it operates in the same rare ophthalmology space with a focus on inherited retinal dystrophies, and its former SVP/Ophthalmology TA Head (Carlos Quezada-Ruiz) is now Alkeus's CMO.
• Kodiak Sciences: Clinical-stage ophthalmology company developing therapeutics for retinal diseases including AMD. Comparable to Alkeus as a retinal-focused biotech pursuing novel mechanisms for high-prevalence retinal indications with a similar pre-commercial, late-stage clinical profile.
• Adverum Biotechnologies: Gene therapy company focused on serious ocular diseases, with lead programs in wet AMD and diabetic macular edema. Comparable as a late-stage ophthalmology biotech targeting retinal vascular and degenerative indications with a similar clinical-stage, capital-intensive profile.
• REGENXBIO: Clinical-stage gene therapy company with programs in retinal diseases (wet AMD, diabetic retinopathy) and rare ophthalmology. Comparable to Alkeus as a retinal-disease-focused biotech pursuing novel modality approaches for sight-threatening conditions.

Emerging players

• Aldeyra Therapeutics: Clinical-stage biotech developing therapies for rare ocular and inflammatory diseases, including retinitis pigmentosa and other retinal conditions. Comparable to Alkeus as a small-cap, late-clinical-stage rare-ophthalmology biotech with similar regulatory pathway dynamics.
• Annexon Biosciences: Clinical-stage biotech with a lead program (vonaprument) in geographic atrophy secondary to AMD. Comparable to Alkeus as a clinical-stage retina competitor in GA with similar pre-commercial profile and indication overlap.
• Ocugen: Clinical-stage biotech with a pipeline including inherited retinal disease programs (e.g., Stargardt and other ABCA4-related dystrophies via OCU410ST). Direct competitor to Alkeus in Stargardt disease, pursuing a gene-therapy modifier approach rather than an oral small molecule.

Broad incumbents

• Novartis (Gyroscope Therapeutics): Acquired Gyroscope Therapeutics and its lead GT005 gene therapy program for geographic atrophy secondary to AMD. Comparable to Alkeus as a large-pharma participant in the GA competitive set and a potential strategic acquirer of late-stage ophthalmology biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/alkeuspharma
• Facebookfacebook.com/Alkeus
• LinkedInlinkedin.com/company/alkeus-pharmaceuticals-inc-
• Instagraminstagram.com/alkeuspharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alkeus Pharmaceuticals